Efficacy of desloratadine in intermittent allergic rhinitis: A GA 2LEN study

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 64, Issue 10, 2009, Pages 1516-1523

  Bousquet, J ^a   Bachert, C ^b   Canonica, G W ^c   Mullol, J ^d   Van Cauwenberge, P ^b   Bindslev Jensen, C ^e   Fokkens, W J ^f   Ring, J ^g   Keith, P ^h   Lorber, R ⁱ   Zuberbier, T ^j  

^a HÔPITAL ARNAUD DE VILLENEUVE   (France)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c UNIVERSITY OF GENOA   (Italy)

^d INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^e ODENSE UNIVERSITY HOSPITAL   (Denmark)

^f ACADEMIC MEDICAL CENTER   (Netherlands)

^g TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^h MCMASTER UNIVERSITY   (Canada)

ⁱ MERCK RESEARCH LABORATORIES   (United States)

^j CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

more..

Author keywords

ARIA; Desloratadine; Intermittent allergic rhinitis; Quality of life; Randomized controlled trial; Work

Indexed keywords

DESLORATADINE; PLACEBO;

ADULT; ALLERGIC RHINITIS; ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; SEDATION; SIDE EFFECT; SOMNOLENCE; THIRST; TREATMENT RESPONSE; VISUAL ANALOG SCALE;

ADULT; DOUBLE-BLIND METHOD; FEMALE; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; LORATADINE; MALE; MIDDLE AGED; QUALITY OF LIFE; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 70349214915     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/j.1398-9995.2009.02115.x     Document Type: Article

References (37)

1. Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001 108 : S147 334.
2. Ciprandi G, Cirillo I, Vizzaccaro A, Tosca M, Passalacqua G, Pallestrini E et al. Seasonal and perennial allergic rhinitis: is this classification adherent to real life? Allergy 2005 60 : 882 887.
3. Bousquet J, Khaltaev N, Cruz A, Denburg J, Fokkens W, Weel CV et al. Allergic rhinitis and its impact on asthma (ARIA) 2008 update. Allergy 2008 63 : 8 160.
4. Bauchau V, Durham SR. Epidemiological characterization of the intermittent and persistent types of allergic rhinitis. Allergy 2005 60 : 350 353.
5. Bousquet J, Annesi-Maesano I, Carat F, Leger D, Rugina M, Pribil C et al. Characteristics of intermittent and persistent allergic rhinitis: DREAMS study group. Clin Exp Allergy 2005 35 : 728 732.
6. Bachert C, Bousquet J, Canonica GW, Durham SR, Klimek L, Mullol J et al. Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis. J Allergy Clin Immunol 2004 114 : 838 844.
7. Fantin S, Maspero J, Bisbal C, Agache I, Donado E, Borja J et al. A 12-week placebo-controlled study of rupatadine 10 mg once daily compared with cetirizine 10 mg once daily, in the treatment of persistent allergic rhinitis. Allergy 2008 63 : 924 931.
8. Nayak AS, Schenkel E. Desloratadine reduces nasal congestion in patients with intermittent allergic rhinitis. Allergy 2001 56 : 1077 1080.
9. Leynaert B, Neukirch C, Liard R, Bousquet J, Neukirch F. Quality of life in allergic rhinitis and asthma. A population-based study of young adults. Am J Respir Crit Care Med 2000 162 : 1391 1396.
10. Juniper EF. Measuring health-related quality of life in rhinitis. J Allergy Clin Immunol 1997 99 : S742 S749.
11. Roberts G, Hurley C, Lack G. Development of a quality-of-life assessment for the allergic child or teenager with multisystem allergic disease. J Allergy Clin Immunol 2003 111 : 491 497.
12. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993 4 : 353 365.
13. Bousquet J, Neukirch F, Bousquet PJ, Gehano P, Klossek JM, Le Gal M et al. Severity and impairment of allergic rhinitis in patients consulting in primary care. J Allergy Clin Immunol 2006 117 : 158 162.
14. Bousquet J, Lund VJ, Van Cauwenberge P, Bremard-Oury C, Mounedji N, Stevens MT et al. Implementation of guidelines for seasonal allergic rhinitis: a randomized controlled trial. Allergy 2003 58 : 733 741.
15. Van Cauwenberge P, Juniper EF. Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120 mg, loratadine 10 mg and placebo administered once daily for the treatment of seasonal allergic rhinitis. Clin Exp Allergy 2000 30 : 891 899.
16. Spector SL, Nicklas RA, Chapman JA, Bernstein IL, Berger WE, Blessing-Moore J et al. Symptom severity assessment of allergic rhinitis: part 1. Ann Allergy Asthma Immunol 2003 91 : 105 114.
17. Terreehorst I, Hak E, Oosting AJ, Tempels-Pavlica Z, de Monchy JG, Bruijnzeel-Koomen CA et al. Evaluation of impermeable covers for bedding in patients with allergic rhinitis. N Engl J Med 2003 349 : 237 246.
18. Berger WE, Schenkel EJ, Mansfield LE. Safety and efficacy of desloratadine 5 mg in asthma patients with seasonal allergic rhinitis and nasal congestion. Ann Allergy Asthma Immunol 2002 89 : 485 491.
19. Baena-Cagnani CE, Berger WE, DuBuske LM, Gurne SE, Stryszak P, Lorber R et al. Comparative effects of desloratadine versus montelukast on asthma symptoms and use of beta 2-agonists in patients with seasonal allergic rhinitis and asthma. Int Arch Allergy Immunol 2003 130 : 307 313.
20. Berger WE, Lumry WR, Meltzer EO, Pearlman DS. Efficacy of desloratadine, 5 mg, compared with fexofenadine, 180 mg, in patients with symptomatic seasonal allergic rhinitis. Allergy Asthma Proc. 2006 27 : 214 223.
21. Meltzer EO, Jalowayski AA, Vogt K, Iezzoni D, Harris AG. Effect of desloratadine therapy on symptom scores and measures of nasal patency in seasonal allergic rhinitis: results of a single-center, placebo-controlled trial. Ann Allergy Asthma Immunol 2006 96 : 363 368.
22. Pradalier A, Neukirch C, Dreyfus I, Devillier P. Desloratadine improves quality of life and symptom severity in patients with allergic rhinitis. Allergy 2007 62 : 1331 1334.
23. Canonica GW, Tarantini F, Compalati E, Penagos M. Efficacy of desloratadine in the treatment of allergic rhinitis: a meta-analysis of randomized, double-blind, controlled trials. Allergy 2007 62 : 359 366.
24. Simons FE, Prenner BM, Finn A Jr. Efficacy and safety of desloratadine in the treatment of perennial allergic rhinitis. J Allergy Clin Immunol 2003 111 : 617 622.
25. Kim K, Sussman G, Hebert J, Lumry W, Lutsky B, Gates D. Desloratadine therapy for symptoms associated with perennial allergic rhinitis. Ann Allergy Asthma Immunol 2006 96 : 460 465.
26. Van Cauwenberge P, Watelet JB, Van Zele T, Bousquet J, Burney P, Zuberbier T. Spreading excellence in allergy and asthma: the GA2 LEN (Global Allergy and Asthma European Network) project. Allergy 2005 60 : 858 864.
27. Frew AJ. GA2LEN - the global allergy and asthma European network. Clin Exp Allergy 2005 35 : 122 125.
28. International Consensus Report on Diagnosis and Management of Rhinitis. International Rhinitis Management Working Group. Allergy 1994 49 : 1 34.
29. Heinzerling L, Frew AJ, Bindslev-Jensen C, Bonini S, Bousquet J, Bresciani M et al. Standard skin prick testing and sensitization to inhalant allergens across Europe - a survey from the GALEN network. Allergy 2005 60 : 1287 1300.
30. Bousquet PJ, Combescure C, Neukirch F, Klossek JM, Mechin H, Daures JP et al. Visual analog scales can assess the severity of rhinitis graded according to ARIA guidelines. Allergy 2007 62 : 367 372.
31. Bousquet PJ, Fabbro-Peray P, Janin N, Annesi-Maesano I, Neukirch F, Daures JP et al. Pilot study assessing the impact of smoking on nasal-specific quality of life. Allergy 2004 59 : 1015 1016.
32. Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf 1999 20 : 109 117.
33. Bachert C, van Cauwenberge P. Desloratadine treatment for intermittent and persistent allergic rhinitis: a review. Clin Ther 2007 29 : 1795 1802.
34. Santos CB, Pratt EL, Hanks C, McCann J, Craig TJ. Allergic rhinitis and its effect on sleep, fatigue, and daytime somnolence. Ann Allergy Asthma Immunol 2006 97 : 579 586.
35. Bousquet J, Demarteau N, Mullol J, van den Akker-van Marle ME, Van Ganse E, Bachert C. Costs associated with persistent allergic rhinitis are reduced by levocetirizine. Allergy 2005 60 : 788 794.
36. Kay GG. The effects of antihistamines on cognition and performance. J Allergy Clin Immunol 2000 105 : S622 S627.
37. Lamb CE, Ratner PH, Johnson CE, Ambegaonkar AJ, Joshi AV, Day D et al. Economic impact of workplace productivity losses due to allergic rhinitis compared with select medical conditions in the United States from an employer perspective. Curr Med Res Opin 2006 22 : 1203 1210.